The Dealmaker Quarterly

The Dealmaker Quarterly focuses on current analysis with top editors offering unique perspective and insight into the market-moving trends, ground-breaking transactions, winning tactics and strategies and the movers and shakers behind them.

Request Free Trial

Join our community of dealmakers and advisers.

Q3 2021: The 2021 Deal Awards

Q1 2021: New Horizons & Top Rising Stars

The Deal’s Q1 Dealmaker Quarterly takes a closer look at how four nascent industries — plant-based food, electric vehicles, cybersecurity and telemedicine — will help form a new world. The edition also features The Deal Top Rising Stars: Class of 2021 honorees, which identifies the top recently appointed U.S.-based M&A-focused partners in the legal world as nominated by their peers.

Q4 2020: ESG: Beyond the Initials & Top Women in Dealmaking

The Deal’s Q4 Dealmaker Quarterly takes a close look at the environmental, social and governance movement to examine just how seriously the financial world is taking these issues. The edition also features The Deal’s 2020 Top Women in Dealmaking honorees, which includes the top women in the legal world as nominated by their peers.

Q3 2020: The 2020 Deal Awards & Coping with Covid

The Q3 Dealmaker Quarterly features the The Deal’s Large Cap and Middle Market Awards for 2020 and weighs the impact of Covid-19 on the dealmaking world.

Q1 2020: New World, New Rules

The Q1 Dealmaker Quarterly offers readers a deep dive into what the November U.S. presidential election could mean for antitrust, corporate governance, shareholder activism and private equity. The Quarterly also includes profiles of the latest crop of M&A partners at law firms, whom we christen Rising Stars.

The Dealmaker Quarterly reaches 350,000+ Corporate Dealmakers and their Advisers

For more information, including how to reach the full subscriber base

of The Deal, please contact Jenney.Smith@TheDeal.com

News From The Deal

Drinks With The Deal: Willkie's Tariq Mundiya

Willkie head of litigation Tariq Mundiya discusses the Williams poison pill case from earlier this year as well as the CytoDyn decision and the evolution of Delaware's Caremark doctrine in this week's Drinks With The Deal podcast.

Drinks With The Deal: Squire Patton Boggs' James Barresi

James Barresi, who heads the firm's financial services practice, explains how his time as an in-house lawyer at US Bancorp in the 1990s has shaped his approach to private practice and how he works with clients considering a deal.

Book Review: Consider the Cocktail

The new 'Oxford Companion to Spirits & Cocktails' treats the beverages in all of their aspects from production to history to brand management.